We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons Why Investments in Rexnord Should Be Avoided for Now
Read MoreHide Full Article
Rexnord Corporation seems to have lost its sheen to the adverse impacts of the coronavirus outbreak, forex woes and high leverage. Also, weak price performance and lowered earnings estimates indicate bearish sentiments for the stock.
The Milwaukee, WI-based company has a market capitalization of $3.1 billion and a Zacks Rank #4 (Sell) at present. It belongs to the Zacks Manufacturing – Electronics industry, currently at the bottom 21% (with the rank of 201) of more than 250 Zacks industries.
We believe that the industry is suffering from global uncertainties, unfavorable movements in foreign currencies, cost-related headwinds, supply-side challenges and other woes. However, favorable governmental policies might be a relief.
Notably, Rexnord’s earnings surpassed estimates by 14.3% in third-quarter fiscal 2020 (ended Dec 31, 2019), while sales lagged the same by 0.8%.
In the past three months, the company's shares have fallen 22.5% compared with the industry’s decline of 26.4%.
Factors Affecting Investment Appeal
Coronavirus-Related Worries: Rexnord believes that the demand for its products will be adversely impacted by the pandemic. It has also withdrawn its share buyback program for now, while continues with its dividend policy.
For fiscal 2020 (ended March 2020, results are awaited), Rexnord expects core sales growth of 1% year over year. The estimate suggests a year-over-year decline from 6% growth registered in fiscal 2019.
High Debts: High debts increase financial obligations and, in turn, hurt profitability. At the end of the first three quarters of fiscal 2020 (ended December 2019), Rexnord’s long-term debts were $1,147.2 million. During this period, the company raised $725 million from borrowings of debt.
Further, Rexnord appears more leverage than the industry, with the respective long-term debt-to-capital figure of 45.6% and 31.4%.
Forex Woes: The presence in the United States, Europe and Canada has exposed Rexnord to geopolitical issues, macroeconomic challenges and unfavorable movements in foreign currencies. In the third quarter of fiscal 2020, forex woes affected the company’s sales by 1%.
Persistence of such issues might pose concerns for Rexnord.
Bottom-Line Estimate Trend: The Zacks Consensus Estimate for the company’s earnings has been revised downward in the past 60 days. The consensus estimate for earnings per share is currently pegged at $1.98 for fiscal 2020 and $1.62 for fiscal 2021 (ending March 2021), reflecting no change and a decline of 22.9% from the respective 60-day-ago figures.
Notably, two downward revisions were recorded for fiscal 2020 earnings as against one upward revision. Further, there were five downward revisions and no upward revision for fiscal 2021.
Rexnord’s Performance Versus Industry Peers
The company has underperformed three industry peers in the past three months. Three such stocks are Franklin Electric Co., Inc. (FELE - Free Report) , Eaton Corporation plc (ETN - Free Report) and A. O. Smith Corporation (AOS - Free Report) , with respective three-month declines of 16.6%, 16.1% and 12.6%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Reasons Why Investments in Rexnord Should Be Avoided for Now
Rexnord Corporation seems to have lost its sheen to the adverse impacts of the coronavirus outbreak, forex woes and high leverage. Also, weak price performance and lowered earnings estimates indicate bearish sentiments for the stock.
The Milwaukee, WI-based company has a market capitalization of $3.1 billion and a Zacks Rank #4 (Sell) at present. It belongs to the Zacks Manufacturing – Electronics industry, currently at the bottom 21% (with the rank of 201) of more than 250 Zacks industries.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We believe that the industry is suffering from global uncertainties, unfavorable movements in foreign currencies, cost-related headwinds, supply-side challenges and other woes. However, favorable governmental policies might be a relief.
Notably, Rexnord’s earnings surpassed estimates by 14.3% in third-quarter fiscal 2020 (ended Dec 31, 2019), while sales lagged the same by 0.8%.
In the past three months, the company's shares have fallen 22.5% compared with the industry’s decline of 26.4%.
Factors Affecting Investment Appeal
Coronavirus-Related Worries: Rexnord believes that the demand for its products will be adversely impacted by the pandemic. It has also withdrawn its share buyback program for now, while continues with its dividend policy.
For fiscal 2020 (ended March 2020, results are awaited), Rexnord expects core sales growth of 1% year over year. The estimate suggests a year-over-year decline from 6% growth registered in fiscal 2019.
High Debts: High debts increase financial obligations and, in turn, hurt profitability. At the end of the first three quarters of fiscal 2020 (ended December 2019), Rexnord’s long-term debts were $1,147.2 million. During this period, the company raised $725 million from borrowings of debt.
Further, Rexnord appears more leverage than the industry, with the respective long-term debt-to-capital figure of 45.6% and 31.4%.
Forex Woes: The presence in the United States, Europe and Canada has exposed Rexnord to geopolitical issues, macroeconomic challenges and unfavorable movements in foreign currencies. In the third quarter of fiscal 2020, forex woes affected the company’s sales by 1%.
Persistence of such issues might pose concerns for Rexnord.
Bottom-Line Estimate Trend: The Zacks Consensus Estimate for the company’s earnings has been revised downward in the past 60 days. The consensus estimate for earnings per share is currently pegged at $1.98 for fiscal 2020 and $1.62 for fiscal 2021 (ending March 2021), reflecting no change and a decline of 22.9% from the respective 60-day-ago figures.
Rexnord Corporation Price and Consensus
Rexnord Corporation price-consensus-chart | Rexnord Corporation Quote
Notably, two downward revisions were recorded for fiscal 2020 earnings as against one upward revision. Further, there were five downward revisions and no upward revision for fiscal 2021.
Rexnord’s Performance Versus Industry Peers
The company has underperformed three industry peers in the past three months. Three such stocks are Franklin Electric Co., Inc. (FELE - Free Report) , Eaton Corporation plc (ETN - Free Report) and A. O. Smith Corporation (AOS - Free Report) , with respective three-month declines of 16.6%, 16.1% and 12.6%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>